Andrew Koenig, DO, is Medical Director of the Inflammation and Immunology Group at Pfizer. He earned his medical degree from the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine in Stratford, New Jersey. He completed an internship and residency at the same institution, where he was also chief resident. He then completed a fellowship in rheumatology at Thomas Jefferson University in Philadelphia, Pennsylvania, where he was named Outstanding Teaching Fellow of the Year in 2000-2001. Dr. Koenig has authored numerous articles for peer-reviewed journals, and he is a Fellow of the American College of Rheumatology.
At Pfizer, he is currently responsible for the medical oversight of the Inflammation and Immunology business in North America with assets in various stages of development. Additionally he has designed, conducted, and reported on late-phase clinical trials in rheumatoid arthritis and ankylosing spondylitis. Before joining Pfizer, he was in private practice in New Jersey, where he conducted clinical research and provided a full scope of rheumatology patient care activities in both the inpatient and outpatient settings.